Modulatory Effects of Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy
Resveratrol Supplement Along With and Without Low Glycemic Index Diet Among Obese Patients With Diabetic Nephropathy
This 12-week randomized controlled trial evaluated the effects of resveratrol supplementation with and without a low glycemic index (LGI) diet in obese patients with diabetic nephropathy. Resveratrol, particularly at the higher dose combined with an LGI diet, significantly improved anthropometric, hepatic, renal, and biochemical parameters, including BMI, liver enzymes, BUN, UPCR, serum uric acid, phosphorus, and albumin levels. These findings suggest that resveratrol may serve as an effective nutraceutical adjunct to dietary modification for improving renal and metabolic health in diabetic nephropathy patients.
研究概览
地位
详细说明
This randomized controlled trial investigated the modulatory effects of resveratrol supplementation, with and without a low glycemic index (LGI) diet, among 102 obese patients with diabetic nephropathy over a 12-week intervention period. Participants were randomly allocated into three groups, including a placebo group and two treatment groups receiving different doses of resveratrol. Clinical, anthropometric, and biochemical parameters were assessed at baseline and after the intervention to determine the efficacy of the treatments.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Dr. Sana Noreen, PhD
- 电话号码:03018661160
- 邮箱:sana.noreen@dnsc.uol.edu.pk
学习地点
-
-
Punjab Province
-
Lahore、Punjab Province、巴基斯坦、54000
- Sana Noreen
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:• Adults aged (40-60) years
- Obese individuals - BMI ≥ 30.0 kg/m²
- Individuals with Fasting Plasma Glucose (FPG) ≤130 mg/dL
- Individuals with HbA1c ≤ 8% (≤64 mmol/mol).
- Urine albumin-creatinine ratio (UACR) ≥30 mg/g
- Serum creatinine ≤2 mg/dL.
- Blood urea nitrogen (BUN) ≤ 20 mg/dL
- Estimated GFR (eGFR) ≥ 60 ml/min
- Inflammatory and stress biomarkers through TNF-α > 8.1 pg/mL and C-Reactive Protein (CRP) > 3 mg/L.
- Liver function test markers, ALT > 56 U/L, AST > 40 U/L, ALP > 147 U/L.
- Lipid profile levels, TC ≥ 200 mg/dL, TG ≥ 150 mg/dL, LDL ≥ 100 mg/dL, HDL ≤ 40 mg/dL.
Exclusion Criteria:• Pregnancy or lactation.
- Allergic to resveratrol.
- Liver failure (acute or chronic).
- Uncontrolled hypertension (BP ≥140/90 mmHg).
- Congestive heart failure.
- History of malignancy.
- Bilateral renal artery stenosis.
- Any systemic disease other than diabetes.
- Active infection or rheumatological disorder.
- Use of warfarin or other anticoagulants.
学习计划
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:PLACEBO T0
1 starch capsule of 300 mg along with their regular diet |
1 starch capsule of 300 mg along with their regular diet |
|
实验性的:1 resveratrol capsule of 300 mg per day T1
1 resveratrol capsule of 300 mg per day along with a low glycemic index diet, once a day |
1 resveratrol capsule of 300 mg per day along with a low glycemic index diet, ONCE A DAY |
|
实验性的:1 resveratrol capsules of 300 mg per day along with a low glycemic index diet, TWICE A DAY T2
1 resveratrol capsules of 300 mg per day along with a low glycemic index diet, TWICE A DAY |
1 resveratrol capsule of 300 mg per day along with a low glycemic index diet, TWICE A DAY |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
LIVER ENZYMES
大体时间:12 WEEKS
|
liver enzymes were assessed (AST, ALT, ALP) |
12 WEEKS
|
|
LIPID PROFILE (TC,TG,LDL, HDL)
大体时间:12 week
|
lipid profile assessed |
12 week
|
|
GLUCOSE (Fasting glucose)
大体时间:12 weeks
|
fasting glucose assessed |
12 weeks
|
|
weight (kg)
大体时间:12 weeks
|
weight |
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
INFLAMAMATION
大体时间:12 WEEKS
|
inflammation was assessed through CRP |
12 WEEKS
|
合作者和调查者
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.